Literature DB >> 30948222

The effectiveness of maternal pertussis vaccination in protecting newborn infants in Brazil: A case-control study.

Eder Gatti Fernandes1, Ana Paula S Sato2, Lourdes R A Vaz-de-Lima3, Marcela Rodrigues4, Daniela Leite5, Cyro A de Brito3, Expedito J A Luna6, Telma Regina M P Carvalhanas4, Maria Lígia Bacciote Nerger Ramos7, Helena Keico Sato8, Euclides A de Castilho9.   

Abstract

INTRODUCTION: In 2014, the Brazilian Ministry of Health (MoH) recommended Tdap to pregnant women in response to a significant increase in the incidence of pertussis among infants. The present study assessed the effectiveness of maternal immunization in preventing pertussis in infants.
METHODS: An unmatched case-control study was undertaken in São Paulo State, Brazil from February 2015 to July 2016. Cases were infants aged <8 weeks at onset of pertussis reported to the Surveillance System and confirmed by real-time polymerase chain reaction or culture. Four to six healthy infants were selected as controls per case from birth certificates in the Information System on Live Births database. General characteristics and mother's vaccination status were compared between cases and controls. The vaccine effectiveness (VE) was calculated as 1 - odds ratio (OR). For the adjusted VE, the OR was calculated using logistic regression analysis.
RESULTS: Forty-two cases and 248 controls were enrolled in the study. Mothers of 8 cases (19.1%) and 143 controls (57.4%) were vaccinated during pregnancy, resulting in an unadjusted VE of 82.6% (95% confidence interval [CI], 60.8-92.3%). The VE was unchanged after adjusting for maternal age and monthly household income.
CONCLUSION: Maternal pertussis vaccination during pregnancy was effective in protecting infants aged <8 weeks from pertussis.
Copyright © 2019 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Bordetella pertussis; Brazil; Case-control study; Maternal immunization; Pertussis vaccine

Year:  2019        PMID: 30948222     DOI: 10.1016/j.vaccine.2019.03.049

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  5 in total

1.  Lessons from a mature acellular pertussis vaccination program and strategies to overcome suboptimal vaccine effectiveness.

Authors:  Ousseny Zerbo; Bruce Fireman; Nicola P Klein
Journal:  Expert Rev Vaccines       Date:  2021-10-08       Impact factor: 5.683

2.  The impact of maternal RSV vaccine to protect infants in Gavi-supported countries: Estimates from two models.

Authors:  Ranju Baral; Xiao Li; Lander Willem; Marina Antillon; Alba Vilajeliu; Mark Jit; Philippe Beutels; Clint Pecenka
Journal:  Vaccine       Date:  2020-06-22       Impact factor: 3.641

3.  Factors Influencing Maternal Antepartum Tdap Vaccination.

Authors:  Henry H Bernstein; Stephanie Tong-Miller; Shannon S Cleary; Margaret Sherin; Cathie Spino
Journal:  Matern Child Health J       Date:  2022-09-29

Review 4.  Global Perspectives on Immunization During Pregnancy and Priorities for Future Research and Development: An International Consensus Statement.

Authors:  Bahaa Abu-Raya; Kirsten Maertens; Kathryn M Edwards; Saad B Omer; Janet A Englund; Katie L Flanagan; Matthew D Snape; Gayatri Amirthalingam; Elke Leuridan; Pierre Van Damme; Vana Papaevangelou; Odile Launay; Ron Dagan; Magda Campins; Anna Franca Cavaliere; Tiziana Frusca; Sofia Guidi; Miguel O'Ryan; Ulrich Heininger; Tina Tan; Ahmed R Alsuwaidi; Marco A Safadi; Luz M Vilca; Nasamon Wanlapakorn; Shabir A Madhi; Michelle L Giles; Roman Prymula; Shamez Ladhani; Federico Martinón-Torres; Litjen Tan; Lessandra Michelin; Giovanni Scambia; Nicola Principi; Susanna Esposito
Journal:  Front Immunol       Date:  2020-06-24       Impact factor: 7.561

5.  Protective effect of exclusive breastfeeding and effectiveness of maternal vaccination in reducing pertussis-like illness.

Authors:  Renata Medeiros do Nascimento; Paulo Neves Baptista; Katiuscia Araújo de Miranda Lopes; Analíria Moraes Pimentel; Fábia da Silva Pereira Cruz; Ricardo Arraes de Alencar Ximenes
Journal:  J Pediatr (Rio J)       Date:  2021-01-16       Impact factor: 2.990

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.